Our findings in HepG2 are a first step towards further investigations in vivo to deeply characterize the role of LncRNAs in the positive effect of GLP-1R agonists on NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.